BridgeBio is significantly advanced its development of a new treatment for cardiac amyloidosis, utilizing the investigational drug. Initial clinical results indicates significant improvements for those diagnosed with a severe condition. This focus underscores the company’s commitment to managing critical healthcare demands in the heart disease f… Read More